Ampio Pharma's Inhaled COVID-19 Treatment Shows 78% Improvement In All-Cause Mortality

  • Ampio Pharmaceuticals Inc AMPE revealed positive results from its AP-014 Phase 1 trial utilizing inhaled Ampion in treating respiratory distress in COVID-19 patients. 
  • The study met its primary endpoint and showed an even greater improvement in all-cause mortality over patients treated using Standard of Care (SOC) than initially reported.
  • Mortality in the SOC group was 24%, while that in the group treated with SOC and Ampion was only 5%,
  • Preliminary results reported in March showed a lower all-cause mortality rate of 8% in the Ampion group, compared to 21% in the standard of care alone.
  • The average hospital length of stay was four days less for the Ampion group than the patients receiving SOC.
  • Separately, the Phase 1 study using Ampion to address the respiratory symptoms experienced by COVID-19 "Long Haulers" is awaiting Investigational Review Board approval and is expected to commence enrollment shortly.
  • Ampio also received a positive response from the FDA on its plans for its Phase 3 trial utilizing intra-articular injection of Ampion for treating osteoarthritis of the knee.
  • The company will provide updates on its plans for this trial at its upcoming May 5th earnings call.
  • Price Action: AMPE shares are down 3.2% at $1.93 in market trading hours on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareSmall CapGeneralBriefsCovid-19COVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!